Aura Biosciences, Inc. (NASDAQ:AURA) Shares Sold by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. reduced its position in Aura Biosciences, Inc. (NASDAQ:AURA) by 19.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,351 shares of the company’s stock after selling 11,704 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.10% of Aura Biosciences worth $422,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. American Century Companies Inc. purchased a new stake in Aura Biosciences during the 2nd quarter worth approximately $119,000. American International Group Inc. boosted its holdings in Aura Biosciences by 27.4% in the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after purchasing an additional 3,782 shares during the period. Virtu Financial LLC acquired a new position in Aura Biosciences during the 1st quarter worth $144,000. SG Americas Securities LLC acquired a new stake in Aura Biosciences in the 3rd quarter valued at about $169,000. Finally, Rhumbline Advisers boosted its stake in shares of Aura Biosciences by 39.6% in the 2nd quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after buying an additional 18,011 shares during the period. Institutional investors and hedge funds own 96.75% of the company’s stock.

Aura Biosciences Stock Up 3.4 %

Shares of AURA stock opened at $9.31 on Friday. The stock’s 50-day moving average price is $9.73 and its 200 day moving average price is $8.63. The stock has a market capitalization of $465.03 million, a PE ratio of -5.38 and a beta of 0.33. Aura Biosciences, Inc. has a 52-week low of $6.63 and a 52-week high of $12.38.

Aura Biosciences (NASDAQ:AURA) last released its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. Analysts expect that Aura Biosciences, Inc. will post -1.66 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Los Pinos Elisabet De sold 24,992 shares of the company’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $12.04, for a total transaction of $300,903.68. Following the transaction, the insider now owns 329,847 shares of the company’s stock, valued at $3,971,357.88. This represents a 7.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Julie B. Feder sold 25,131 shares of the stock in a transaction on Friday, October 18th. The stock was sold at an average price of $12.03, for a total value of $302,325.93. Following the completion of the transaction, the chief financial officer now owns 134,276 shares of the company’s stock, valued at $1,615,340.28. The trade was a 15.77 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 79,081 shares of company stock worth $891,353. 5.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

AURA has been the subject of a number of recent research reports. BTIG Research lifted their price target on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. JMP Securities upped their price objective on Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research report on Friday, September 13th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 target price on shares of Aura Biosciences in a research report on Thursday, November 14th. Finally, Cowen restated a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Aura Biosciences has a consensus rating of “Buy” and a consensus target price of $23.00.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.